The Advaxis Inc (NASDAQ:ADXS) stock has continued with its momentum this morning and already jumped by 10%.
The stock had come into focus yesterday after the clinical stage biotech firm announced the updated data from the Phase 1/1 study of its product ADSX 503 which is currently progressing. In this study, the product is being evaluated in combination with KEYTRUDA. The data is going to be presented by Advaxis by way of a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting.
The results from the early rounds of the study have proven to be quite encouraging and the first 9 patients who could be evaluated demonstrated a disease control rate of 44%. The Chief Executive Officer of the company Ken Berlin also spoke about the results. He stated that these updated results supported the possibility of deploying ADSX 503 in order to enhance sensitivity in patients when it comes to check point inhibitors.